Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Aardvark halts obesity trials, putting entire pipeline on pause
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Darren Incorvaia
Mar 24, 2026 4:00am
Pfizer, Valneva miss Lyme shot ph. 3 goal but plan approval push
Mar 23, 2026 6:45am
Immutep's ph. 3 failure surprises analysts, sinks stock
Mar 13, 2026 9:53am
Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study
Feb 24, 2026 9:15am
Gossamer Bio fails phase 3 pulmonary arterial hypertension trial
Feb 23, 2026 9:50am
Novo's CagriSema loses phase 3 obesity battle against Zepbound
Feb 23, 2026 7:20am
